🔴 Icecure Medical is trading 6.23% down today, with no verified negative company-specific catalyst found

Icecure Medical is trading 6.23% down at $3.01, with no verified negative company-specific catalyst found for the August 6, 2026 decline.

• Adventist Health Glendale became the first site approved to enroll patients in the post-marketing ChoICE study for ProSense breast-cancer treatment.
• The positive development does not explain the selloff, which contrasts with healthcare-sector strength and modestly lower broader U.S. indexes.
• Trading appears volatile after the stock reversed from its August 5 close of $3.21.